Company
LGC Capital Ltd
Headquarters: Montreal, QC, Canada
CEO: Mr. Ferras Zalt
Market Cap
C$13.1 Million
CAD as of Jan. 1, 2024
US$9.9 Million
LGC Capital Ltd Categories
Canada Healthcare Drug Manufacturers—Specialty & GenericCanada Healthcare Canada Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cannabis related businesses, which are fully licensed for cultivation, production, and/or sale of medical and specialty cannabis and cannabis derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. is based in Montreal, Canada.
Top 1-year algo backtest: +181.22%
$10,000 in June 2023 would now be $28,122 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
LGC Capital Ltd has the following listings and related stock indices.
Stock: TSXV: ELXR wb_incandescent